Bommakanti Krishna K, Kosaraju Nikitha, Tam Kenric, Chai-Ho Wanxing, St John Maie
Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1624, USA.
UCLA Head and Neck Cancer Program (HNCP), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1624, USA.
Cancers (Basel). 2023 Jun 26;15(13):3348. doi: 10.3390/cancers15133348.
The incidence of non-melanoma skin cancer (NMSC) continues to rise, and more than one million cases are diagnosed in the United States each year. The increase in prevalence has been attributed to increased lifespan and improvements in survival for conditions that increase the risk of these malignancies. Patients who are immunocompromised have a higher risk of developing NMSC compared to the general population. In immunosuppressed patients, a combination of prevention, frequent surveillance, and early intervention are necessary to reduce morbidity and mortality. In this review, we collate and summarize current knowledge regarding pathogenesis of head and neck cutaneous SCC and BCC within immunocompromised patients, examine the potential role of the immune response in disease progression, and detail the role of novel immunotherapies in this subset of patients.
非黑色素瘤皮肤癌（NMSC）的发病率持续上升，美国每年有超过100万例病例被诊断出来。患病率的增加归因于寿命延长以及增加这些恶性肿瘤风险的疾病在生存率方面的改善。与普通人群相比，免疫功能低下的患者发生NMSC的风险更高。在免疫抑制患者中，预防、频繁监测和早期干预相结合对于降低发病率和死亡率是必要的。在这篇综述中，我们整理并总结了关于免疫功能低下患者头颈部皮肤鳞状细胞癌（SCC）和基底细胞癌（BCC）发病机制的现有知识，研究免疫反应在疾病进展中的潜在作用，并详细阐述新型免疫疗法在这一患者亚组中的作用。
